Correlation Between Karyopharm Therapeutics and Viking Therapeutics
Can any of the company-specific risk be diversified away by investing in both Karyopharm Therapeutics and Viking Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Karyopharm Therapeutics and Viking Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Karyopharm Therapeutics and Viking Therapeutics, you can compare the effects of market volatilities on Karyopharm Therapeutics and Viking Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Karyopharm Therapeutics with a short position of Viking Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Karyopharm Therapeutics and Viking Therapeutics.
Diversification Opportunities for Karyopharm Therapeutics and Viking Therapeutics
0.58 | Correlation Coefficient |
Very weak diversification
The 3 months correlation between Karyopharm and Viking is 0.58. Overlapping area represents the amount of risk that can be diversified away by holding Karyopharm Therapeutics and Viking Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Viking Therapeutics and Karyopharm Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Karyopharm Therapeutics are associated (or correlated) with Viking Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Viking Therapeutics has no effect on the direction of Karyopharm Therapeutics i.e., Karyopharm Therapeutics and Viking Therapeutics go up and down completely randomly.
Pair Corralation between Karyopharm Therapeutics and Viking Therapeutics
Given the investment horizon of 90 days Karyopharm Therapeutics is expected to under-perform the Viking Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Karyopharm Therapeutics is 2.01 times less risky than Viking Therapeutics. The stock trades about -0.65 of its potential returns per unit of risk. The Viking Therapeutics is currently generating about -0.18 of returns per unit of risk over similar time horizon. If you would invest 5,199 in Viking Therapeutics on September 25, 2024 and sell it today you would lose (997.50) from holding Viking Therapeutics or give up 19.19% of portfolio value over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Together |
Strength | Weak |
Accuracy | 100.0% |
Values | Daily Returns |
Karyopharm Therapeutics vs. Viking Therapeutics
Performance |
Timeline |
Karyopharm Therapeutics |
Viking Therapeutics |
Karyopharm Therapeutics and Viking Therapeutics Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Karyopharm Therapeutics and Viking Therapeutics
The main advantage of trading using opposite Karyopharm Therapeutics and Viking Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Karyopharm Therapeutics position performs unexpectedly, Viking Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Viking Therapeutics will offset losses from the drop in Viking Therapeutics' long position.Karyopharm Therapeutics vs. X4 Pharmaceuticals | Karyopharm Therapeutics vs. Hookipa Pharma | Karyopharm Therapeutics vs. Mereo BioPharma Group | Karyopharm Therapeutics vs. Acumen Pharmaceuticals |
Viking Therapeutics vs. Fate Therapeutics | Viking Therapeutics vs. Caribou Biosciences | Viking Therapeutics vs. Karyopharm Therapeutics | Viking Therapeutics vs. X4 Pharmaceuticals |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Other Complementary Tools
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
CEOs Directory Screen CEOs from public companies around the world |